To bridge this critical growth deficit, the Goldman Sachs 10,000 Small Businesses (10KSB) UK programme has acted as a vital educational and strategic intervention since its launch in 2010. Fully funded by the Goldman Sachs Foundation, the initiative provides high-growth small business leaders and social entrepreneurs with 100 hours of practical business and management education.

The global healthcare ecosystem is undergoing a profound structural transition. For decades, clinical medicine operated under a reactive, "one-size-fits-all" framework. Under this legacy model, clinical interventions were typically initiated only after the manifestation of symptomatic disease, overlooking the granular genetic, metabolic and physiological variations that define individual baselines. Today, a combination of macroeconomic pressures, demographic shifts and rapid

Passive continuous phenotyping represents a paradigm shift in modern clinical medicine, transitioning diagnostic and therapeutic monitoring from reactive, episodic clinical visits to continuous, proactive and ecologically valid tracking of individual physiological baselines. Traditional medical models rely on static, sparse measurements that are highly vulnerable to clinical artifacts, such as "white-coat" hypertension or retrospective recall bias and fail to capture the dyna

The global technology investment landscape experienced a significant consolidation in June 2026 when the Netherlands-listed technology investor Prosus finalised a €400 Million (US$460 million) direct investment into the French digital health and insurtech platform, Alan.

Despite Europe's thriving startup ecosystem, which consistently produces world-class scientific discoveries and breakthrough technologies, innovative enterprises face severe challenges when attempting to scale within the continent. As tech and life science companies transition from early-stage validation to the capital-intensive scaleup phase, they routinely encounter an underdeveloped late-stage venture capital sector. This domestic funding gap, particularly acute in growth

The European healthcare technology and services landscape has entered a structurally distinct phase of maturation, transitioning from the speculative, growth-at-all-costs venture capital paradigms of the post-pandemic era into an era defined by profitable efficiency, clinical validation and platform scale. Following several years of valuation corrections and capital constraints, mergers and acquisitions have become the dominant, necessary exit route for maturing enterprises,

The public equity market for digital health entered a period of pronounced stagnation in 2026, creating a stark paradox for the venture capital ecosystem. While broader healthcare sectors, biotechnology platforms and emergency service providers successfully accessed public capital, not a single core digital health platform completed an initial public offering (IPO) during the first half of the year. This freeze stands in sharp contrast to the momentum of Mid 2025, when a bri

On June 22nd, 2026, ChartSpan Medical Technologies finalised its strategic acquisition of Validic, a prominent personal health data and healthcare Internet of Things (IoT) platform. Operating as a consolidated entity under the ChartSpan banner, the transaction establishes a unified clinical delivery layer that merges full-service virtual care teams with a scaled device-logistics and data normalisation ecosystem. The transaction bridges a historically fragmented healthcare dat

The global medical technology and healthcare technology sectors are undergoing a profound structural realignment, shifting from post-pandemic volume driven consolidation toward highly disciplined portfolio design. Corporate divestitures, spin-offs and carve-outs have become primary mechanisms for multinational healthtech organisations seeking to optimise operating margins, reduce debt and redeploy capital toward high-growth, high-margin clinical categories. Driven by macroeco

Clinical enterprises are undergoing a fundamental transformation in how they deploy, orchestrate and manage artificial intelligence workloads. The rapid integration of high-performance models into core workflows, ranging from real-time diagnostic imaging to predictive patient risk modelling and automated clinical documentation, has exposed the limits of traditional public cloud architectures. In response, healthcare systems are increasingly adopting sovereign artificial intel

The valuation of healthtech and medtech entities represents one of the most complex exercises in corporate finance, requiring analysts to bridge the gap between long-term scientific development, binary regulatory approvals, capital intensive commercialisation and rapid technological obsolescence. Within a discounted cash flow (DCF) model, the terminal value is the single most critical and sensitive component of a company's total implied valuation, typically constituting betwe

The global computing landscape is undergoing a structural realignment. Driven by the rapid scaling of generative artificial intelligence and deep learning, the historical trajectory toward centralised public cloud environments is being challenged by a highly optimised, decentralised paradigm. NVIDIA is at the forefront of this transition, promoting on-premises "AI Factories" and localised hardware architectures as the defining infrastructure for the next decade of technology

Here's what's moved in European HealthTech over the past week, with the sector's attention firmly on Amsterdam. On funding, the standout was Semble's £30M Series C, led by Revaia with Partech and Octopus Ventures, to expand its open, interoperable clinical platform into France and larger European groups. Around it, a cluster of smaller AI-led rounds: 01Health ($15M Series A, specialist healthcare infrastructure, UK),

Deep-tech health monitoring has emerged as a major point of convergence for consumer electronics and longevity science. A notable project in this landscape is Temple, a neuro-technology and biological monitoring startup founded in 2024 by Deepinder Goyal, the founder and executive chairman of the Indian consumer-internet giant Zomato.

Five thousand leaders, one in three of them holding an executive title, descended on the RAI Amsterdam from 15th to 18th June 2026 for HLTH Europe. The call to action this year was "Step Outside", a deliberate nudge to leave the comfort zone, look at familiar problems from unfamiliar angles, and find energy in collaboration across boundaries. For those of us who spend our days on the deal side of digital health, the phrase turned out to be an unusually accurate description of